Carotid Endarterectomy vs. Repeated Carotid Angioplasty and Stenting for In-Stent Restenosis

NCT ID: NCT05390983

Last Updated: 2024-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-25

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal. The objective of the randomized study is to compare the safety and effectiveness of CEA and CAS in patients with in-stent restenosis of the ICA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients: Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal.

Repeated carotid percutaneous transluminal angioplasty with or without stenting: Endovascular interventions are going to be performed in local anesthesia from femoral access. Unfractioned heparin (100 IU/kg bodyweight) will be administered in all patients. The procedures will start with diagnostic angiography. Upon verification of severity and morphology of the in-stent stenosis 90 cm long 6F sheath will be introduced into the CCA. The procedures will be performed using distal filter protection. In severe stenoses predilation with 3 or 4 mm diameter balloon will be carried out. In-stent restenoses will be treated preferentially with 5 mm diameter drug eluting balloon. Atropin, up to the dose of 1.0 milligram, can be administered intravenously to prevent serious bradycardia during dilation. Stent will be placed within previous stent in cases of suboptimal PTA result and the decision will be left to the discretion of the interventional specialist. Whenever possible, double-layer technology stent will be used to ensure supreme wall coverage. Distal filter will be removed followed by the completion angiogram including intracranial arteries. Dual antiplatelet therapy (clopidogrel 75 mg/day and acetylsalicylic acid 100 mg/day) will be administered for at least 6 weeks post-procedure. All patients will undergo pre-procedural laboratory testing regarding clopidogrel resistance. In poor responders clopidogrel is going to be replaced by prasugrel or ticagrelor.

Carotid endarterectomy with stent removal: Surgery will be performed in a general or a local anesthesia (decision will be left to the discretion of the operating team) using a cut in front angle of the sternomastoid muscle. Common carotid artery (CCA) and later internal carotid artery (ICA) and external carotid artery (ECA) will be cut free. Common carotid artery, ICA and ECA will be temporarily closed. Using a longitudinal cut of CCA and ICA, stent with an atherosclerotic plaque will be visualized. The stent and a plaque will be withdrawn under the microscopic control and later a suture of arteriotomy will be performed using a monofil non-absorbent fibre 6/0. Just before the end of surgery, hemostatic process will be controlled and drainage will be done. Surgery will be completed by suture of subcutis and cutis. Unfractioned heparin (100 IU/kg bodyweight) could be administered in all patients just before the arteriotomy. In the case of the insufficient collateral flow into middle cerebral artery after clipping of the CCA and ICA, a temporal shunt could be used. Antiplatelet therapy (Aggrenox, clopidogrel 75 mg/day or acetylsalicylic acid 100 mg/day) will be used continuously in all patients.

Clinical examinations: Standard physical and neurologic examinations will be performed before intervention, 24 hours and 30 days after intervention. Evaluation of the neurologic deficit will be performed using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin scale before, 24 hours and 30 days after intervention.

Randomization: Consecutive patients will be assigned to the carotid endarterctomy with stent removal or repeated carotid percutaneous transluminal angioplasty with or without stenting by a computer-generated 1:1 randomization.

Statistical analysis: All statistical tests will be performed at the Center for Health Research, Faculty of Medicine, University of Ostrava. The normality of distribution of all proceeded data will be checked using the Shapiro-Wilk test. Data with a normal distribution will be reported as the mean ± standard deviation. Parameters not fitting a normal distribution will be presented as the mean, median and interquartile range. Categorical variables in the two arms will be compared by Fisher's exact test. Continuous variables will be compared by the Student's t-test for normally distributed values, or the Mann-Whitney U test. Spearman correlation coefficient and intraclass correlation coefficient will be calculated for the evaluation of interobserver and intraobserver agreements of brain infarction volume measurement. Multiple logistic regression analyses will be used to determine the possible predictors of stroke, TIA, retinal infarction, amaurosis fugax, myocardial infarction or vascular death. All tests will be carried out at an alpha level of significance of 0.05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

In-Stent Carotid Artery Restenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

case-control study
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

carotid endarterectomy

carotid endarterectomy with stent removal

Group Type EXPERIMENTAL

Carotid endarterectomy with stent removal

Intervention Type PROCEDURE

Standard carotid endarterectomy will be extended with the stent removal

repeated angioplasty and stenting

percutaneous transluminal angioplasty with or without stenting

Group Type ACTIVE_COMPARATOR

Carotid endarterectomy with stent removal

Intervention Type PROCEDURE

Standard carotid endarterectomy will be extended with the stent removal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carotid endarterectomy with stent removal

Standard carotid endarterectomy will be extended with the stent removal

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Carotid endarterectomy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* In-stent restenosis in carotid artery 70 - 99 %
* Indication to carotid intervention
* Age 18-80 years
* Functionally independent with a modified Rankin score value of 0 - 2 points
* Signed Informed consent

Exclusion Criteria

* Contraindication to general anesthesia
* Contraindication to angiography (iodine allergy, etc.)
* Technically impossible to perform angioplasty with or without stenting
* Participation in other clinical study within 60 days
* Technically impossible to perform carotid endarterectomy
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Ostrava

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tomas Hrbac, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Ostrava

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Ostrava

Ostrava, Moravskoslezský kraj, Czechia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Czechia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tomas Hrbac, MD, PhD

Role: CONTACT

+420597375402

David Skoloudik, Prof,MD,PhD

Role: CONTACT

+420597375613

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tomas Hrbac, MD, Ph.D.

Role: primary

+420597375402

David Skoloudik, Prof MD PhD

Role: backup

+420597375613

References

Explore related publications, articles, or registry entries linked to this study.

Hrbac T, Fiedler J, Prochazka V, Jonszta T, Roubec M, Pakizer D, Vaclavik D, Netuka D, Heryan T, Skoloudik D. Comparison of carotid endarterectomy and repeated carotid angioplasty and stenting for in-stent restenosis (CERCAS trial): a randomised study. Stroke Vasc Neurol. 2023 Oct;8(5):399-404. doi: 10.1136/svn-2022-002075. Epub 2023 Mar 27.

Reference Type DERIVED
PMID: 36972920 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CZ11032017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Endovascular Treatment of Thoracic Aortic Disease
NCT00583817 ENROLLING_BY_INVITATION NA